BEAM THERAPEUTICS INC. - COMMON STOCK

Beam Therapeutics to Present New Preclinical Data Highlighting Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant at the 64th ASH Annual Meeting

03 Nov 2022 08:01:00 By Nasdaq GlobeNewswire

Beam Therapeutics Presents First In Vivo Data Demonstrating Potential of Multiplex Base Editing Approach to Target Disease Drivers of Chronic Hepatitis B Infection

19 Sep 2022 05:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate at the Wells Fargo 2022 Healthcare Conference

01 Sep 2022 05:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Announces Pipeline and Business Highlights and Reports Second Quarter 2022 Financial Results

09 Aug 2022 05:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference

02 Aug 2022 07:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Present First Research Highlighting Approach to Develop Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant

27 Jun 2022 05:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

03 Jun 2022 05:42:39 By Nasdaq GlobeNewswire

Beam Therapeutics Announces Pipeline and Business Highlights and Reports First Quarter 2022 Financial Results

09 May 2022 05:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in Upcoming May Investor Conferences

04 May 2022 05:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Conference

25 Mar 2022 05:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the Barclays 2022 Global Healthcare Conference

08 Mar 2022 05:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports Pipeline and Business Highlights, Planned 2022 Milestones and Fourth Quarter and Full Year 2021 Financial Results

28 Feb 2022 05:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference

09 Feb 2022 05:30:00 By Nasdaq GlobeNewswire

Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases

10 Jan 2022 05:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports Progress Across Ex Vivo and In Vivo Pipeline of Base Editing Therapeutics and Outlines Key Anticipated 2022 Milestones

09 Jan 2022 08:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

03 Jan 2022 05:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Outlines Long-term Strategy for Base Editing Programs in Sickle Cell Disease and Provides Preclinical Data Updates at ASH

12 Dec 2021 08:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports Preclinical Data Highlighting Multiplex Base Editing Approach to Create Anti-CD5 CAR T-cell Investigational Therapies for T-Cell Malignancies

12 Nov 2021 06:00:02 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the Jefferies 2021 Virtual London Healthcare Conference

11 Nov 2021 05:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to its Board of Directors

08 Nov 2021 05:00:00 By Nasdaq GlobeNewswire